{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Double-Masked Treatment Period', 'Teprotumumab or Placebo 1,2', 'Follow-Up Period', 'Follow-Up', 'Screen', 'Baseline', 'Contact', '48 Weeks 3,4', '24 Weeks', '48 Weeks', 'Clinic Visits', '>', '<', 'Clinic Visits', '>', '2 6', 'Day 6', 'W1', 'W36', 'W4', 'W6', 'W9', 'W12', 'W15', 'W18', 'W21', 'W24\u00b2', 'W28', 'W36', 'W48', 'W60', 'W72', 'W96', 'W120', 'weeks', 'M1', 'M3', 'M6', 'M7', 'M9', 'M12', 'M15', 'M18', 'M24', 'M30', 'predose', 'Randomization', 'Study Week/Month', 'n=38/group', '1', '* Infusion of study drug.', '1.', 'Subjects will be randomized in a 1:1 ratio (stratified by tobacco use status) to receive:', 'a. Teprotumumab 20 mg/kg (10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions); or', 'b. Placebo (placebo q3W for all 8 infusions).', '2. Visit windows are 1 day for Weeks 1 and 4, I 3 days for Weeks 3, 6, 9, 12, 15, 18, and 21, and 7 days for Week 24.', '3.', 'Subjects who are proptosis responders or non-responders who do not elect to participate in the open-label extension study will enter a 48-week', 'Follow-Up Period. Subjects who are responders at Week 24 but relapse during the Follow-Up Period may enter the open-label study and receive', '8 infusions if they meet specified criteria.', '4. Visit windows of I 7 days.', '5. Subjects who complete the Week 72 Visit will be contacted via phone or email by research staff to enquire if any treatment for TED has been', 'received since last study contact.', '6.', 'Subjects', 'will be contacted by phone/email the day following the first and second infusions for safety and tolerability assessments; phone/email', 'contacts will also occur the day after any clinic visit where a subject experiences an infusion-related adverse event.', '7. Subjects who are proptosis non-responders at Week 24 of the double-masked Treatment Period will be offered the option to enter an open-label', 'extension study and receive 8 infusions of teprotumumab 20 mg/kg (10 mg/kg on Day 1 followed by 20 mg/kg for the remaining 7 infusions).', 'Subject Population:', 'Approximately 76 (38/group) male and non-pregnant female subjects between the ages of 18 and 80 years,', \"inclusive, with a clinical diagnosis of Graves' disease associated with moderate-to-severe, active TED and a\", 'CAS > 4 (using 7-item scale) for the most severely affected eye will be enrolled.', 'Inclusion Criteria:', 'Eligible subjects must meet/provide all of the following criteria:', '1. Written informed consent.', '2.', 'Male or female subject between the ages of 18 and 80 years, inclusive, at Screening.', '3.', \"Clinical diagnosis of Graves' disease associated with active TED with a CAS > 4 (on the 7-item scale)\", 'for the most severely affected eye at Screening and Baseline.', '4. Moderate-to-severe active TED (not sight-threatening but has an appreciable impact on daily life),', 'usually associated with one or more of the following: lid retraction >2 mm, moderate or severe soft', 'tissue involvement, exophthalmos > 3 mm above normal for race and gender, and/or inconstant or', 'constant diplopia.', '5. Onset of active TED symptoms (as determined by subject records) within 9 months prior to Baseline.', '6. Subjects must be euthyroid with the baseline disease under control, or have mild hypo- or', 'hyperthyroidism (defined as free thyroxine [FT4] and free triiodothyronine [FT3] levels < 50% above', 'or below the normal limits) at Screening. Every effort should be made to correct the mild hypo- or', 'hyperthyroidism promptly and to maintain the euthyroid state for the full duration of the clinical trial.', '7. Does not require immediate surgical ophthalmological intervention and is not planning corrective', 'surgery/irradiation during the course of the study.', '8.', 'Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 3 times the upper limit of', 'normal (ULN) or serum creatinine <1.5 times the ULN according to age at Screening.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 24 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '9. Diabetic subjects must have well-controlled stable disease (defined as HbA1c < 9.0% with no new', 'diabetic medication [oral or insulin] or more than a 10% change in the dose of a currently prescribed', 'diabetic medication within 60 days prior to Screening).', '10. Women of childbearing potential (including those with an onset of menopause years prior', 'to', 'Screening, non-therapy-induced amenorrhea for <12 months prior to Screening, or not surgically sterile', '[absence of ovaries and/or uterus]) must have a negative serum pregnancy test at Screening and', 'negative urine pregnancy tests at all protocol-specified timepoints (i.e., prior to each dose and through', 'Week 48 of the Follow-Up Period); subjects who are sexually active with a non-vasectomized male', 'partner must agree to use 2 reliable forms of contraception during the trial, one of which is', 'recommended to be hormonal, such as an oral contraceptive. Hormonal contraception must be started at', 'least one full cycle prior to Baseline and continue for 180 days after the last dose of study drug. Highly', 'effective contraceptive methods (with a failure rate less than 1% per year), when used consistently and', 'correctly, includes implants, injectables, combined oral contraceptives, some intrauterine devices', '(IUDs), sexual abstinence or vasectomized partner.', '11. Male subjects must be surgically sterile or, if sexually active with a female partner of childbearing', 'potential, must agree to use a barrier contraceptive method from Screening through 180 days after the', 'last dose of study drug.', '12. Subject is willing and able to comply with the prescribed treatment protocol and evaluations for the', 'duration of the study.', 'Exclusion Criteria:', 'Subjects will be ineligible for study participation if they meet any of the following criteria:', '1. Decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision of 2', 'lines on the Snellen chart, new visual field defect, or color defect secondary to optic nerve involvement', 'within the last 6 months.', '2.', 'Corneal decompensation unresponsive to medical management.', '3.', 'Decrease in CAS of > 2 points in the study eye between Screening and Baseline.', '4.', 'Decrease in proptosis of > 2 mm in the study eye between Screening and Baseline.', '5.', 'Previous orbital irradiation or surgery for TED.', '6.', 'Any steroid use (intravenous [IV] or oral) with a cumulative dose equivalent to > 1 g of', 'methylprednisolone for the treatment of TED. Previous steroid use (IV or oral) with a cumulative dose', 'of <1 g methylprednisolone or equivalent for the treatment of TED and previous use of steroid eye', 'drops is allowed if discontinued at least 4 weeks prior to Screening.', '7. Corticosteroid use for conditions other than TED within 4 weeks prior to Screening (topical steroids for', 'dermatological conditions and inhaled steroids are allowed).', '8.', 'Selenium and biotin must be discontinued 3 weeks prior to Screening and must not be restarted during', 'the clinical trial; however, taking a multivitamin that includes selenium and/or biotin is allowed.', '9. Any previous treatment with rituximab (Rituxan\u00ae or MabTheraR) or tocilizumab (Actemra or', 'Roactemra). Use of any other non-steroid immunosuppressive agent within 3 months prior to', 'Screening.', '10. Use of an investigational agent for any condition within 60 days prior to Screening or anticipated use', 'during the course of the trial.', '11. Identified pre-existing ophthalmic disease that, in the judgment of the Investigator, would preclude', 'study participation or complicate interpretation of study results.', '12. Bleeding diathesis that in the judgment of the Investigator would preclude inclusion in the clinical trial.', '13. Malignant condition in the past 12 months (except successfully treated basal/squamous cell carcinoma', 'of the skin).', '14. Pregnant or lactating women.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 25 of 117']\n\n###\n\n", "completion": "END"}